NLRP3 and myeloid sarcoma: Another study has shown that inhibiting the level of IL-1β in MS patients can have a symptom-relieving effect, but this is based on MS patients who are dependent on the NLRP3 inflammasome [142], which also suggests that only when the NLRP3 inflammasome is activated in MS patients or EAE models can inhibition of IL-1β have the effect of relieving MS symptoms.